Search global stocks & ETFs...Ctrl K
Learn Mode
CPRX
Stock Profile
08-04
Recommended Metric
Score Card
Explore Scores Tab
3.96
Good
Valuation Score
Key Score
1.00
Very Bad
Management
4.00
Good
Growth
1.00
Very Bad
Profitability
2.00
Bad
Fin. Health
4.00
Good
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$31.45
Baseline
High
$37.80
▲
20.19%
Avg
$34.32
▲
9.11%
Low
$31.82
▲
1.16%
Analyst Ratings based on 12 Analysts
Strong Buy
217%
Buy
433%
Hold
650%
Sell
000%
Strong Sell
000%
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.Read More